Introduction: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria (CU), which requires specific triggers to occur. Despite their common occurrence, treatment response rates and predictors of treatment responses are largely lacking in the literature. This study evaluates antihistamine (AH) and omalizumab response rates in the most common CIndU subtypes and examines whether certain features can predict treatment responses. Methods: We retrospectively analyzed CU patients with at least one CIndU subtype and performed comparisons between subgroups, in a total of 423 patients (70% CIndU, 30% chronic spontaneous urticaria [CSU] plus CIndU). Results: The treatment response rates in CIndU were 51.6%, 51.5%, and 86.5% with standard-dose second-generation H1-antihistamines (sgAHs), updosed/combined sgAH, and omalizumab, respectively. Overall AH response was higher in CIndU than CSU plus CIndU (78.3% vs. 62%, p = 0.002) and in symptomatic dermographism (SD) and cold urticaria (ColdU) than cholinergic urticaria (ChoU) (83.2% vs. 78.3 vs. 60.9%, p = 0.04). AH-refractory patients had a longer disease duration (45.2 ± 56.7 months vs. 37 ± 51.9 months, p = 0.04), more angioedema, accompanying CSU, mixed CIndU subtypes (37.5% vs. 21.1%, p = 0.003; 45.1% vs. 27.1%, p = 0.002; 8.8% vs. 2.4%, p = 0.014), and lower baseline urticaria control test scores (5.86 ± 3.3 vs. 8.6 ± 3.6, p < 0.001) than AH-responsive patients. Conclusion: CIndU exhibits a good response to both AHs and omalizumab. Notably, the response to AHs is more pronounced in SD and ColdU compared to ChoU. Disease duration, angioedema, accompanying CSU, mixed CIndU, and lower baseline UCT scores may be used to predict AH treatment outcome in CIndU.

1.
Zuberbier
T
,
Abdul Latiff
AH
,
Abuzakouk
M
,
Aquilina
S
,
Asero
R
,
Baker
D
, et al
.
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
.
Allergy
.
2022
;
77
(
3
):
734
66
.
2.
Magerl
M
,
Altrichter
S
,
Borzova
E
,
Gimenez-Arnau
A
,
Grattan
CE
,
Lawlor
F
, et al
.
The definition, diagnostic testing, and management of chronic inducible urticarias - the EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision
.
Allergy
.
2016
;
71
(
6
):
780
802
.
3.
Maurer
M
,
Hawro
T
,
Krause
K
,
Magerl
M
,
Metz
M
,
Siebenhaar
F
, et al
.
Diagnosis and treatment of chronic inducible urticaria
.
Allergy
.
2019
;
74
(
12
):
2550
3
.
4.
Dice
JP
.
Physical urticaria
.
Immunol Allergy Clin North Am
.
2004
;
24
(
2
):
225
46
. vi.
5.
Ornek Ozdemir
S
,
Kuteyla Can
P
,
Degirmentepe
EN
,
Cure
K
,
Singer
R
,
Kocaturk
E
.
A comparative analysis of chronic inducible urticaria in 423 patients: clinical and laboratory features and comorbid conditions
.
J Eur Acad Dermatol Venereol
.
2024
;
38
(
3
):
513
20
.
6.
Maurer
M
,
Fluhr
JW
,
Khan
DA
.
How to approach chronic inducible urticaria
.
J Allergy Clin Immunol Pract
.
2018
;
6
(
4
):
1119
30
.
7.
Dias
GA
,
Pires
GV
,
Valle
SO
,
Dortas
SDJ
,
Levy
S
,
Franca
AT
, et al
.
Impact of chronic urticaria on the quality of life of patients followed up at a university hospital
.
Bras Dermatol
.
2016
;
91
(
6
):
754
9
.
8.
Dressler
C
,
Werner
RN
,
Eisert
L
,
Zuberbier
T
,
Nast
A
,
Maurer
M
.
Chronic inducible urticaria: a systematic review of treatment options
.
J Allergy Clin Immunol
.
2018
;
141
(
5
):
1726
34
.
9.
Can
PK
,
Salman
A
,
Hosgoren-Tekin
S
,
Kocaturk
E
.
Effectiveness of omalizumab in patients with chronic inducible urticaria: real-life experience from two UCARE centres
.
J Eur Acad Dermatol Venereol
.
2021
;
35
(
10
):
e679
82
.
10.
Buters
TP
,
van der Velden
WAC
,
Abdisalaam
I
,
van Maaren
MS
,
van Doorn
MBA
.
Effectiveness and tolerability of personalized omalizumab treatment in patients with chronic inducible urticaria
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
8
):
3227
9
.
11.
Yu
M
,
Terhorst-Molawi
D
,
Altrichter
S
,
Hawro
T
,
Chen
YD
,
Liu
B
, et al
.
Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response
.
Clin Exp Allergy
.
2021
;
51
(
5
):
730
4
.
12.
Maurer
M
,
Metz
M
,
Brehler
R
,
Hillen
U
,
Jakob
T
,
Mahler
V
, et al
.
Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence
.
J Allergy Clin Immunol
.
2018
;
141
(
2
):
638
49
.
13.
Fok
JS
,
Kolkhir
P
,
Church
MK
,
Maurer
M
.
Predictors of treatment response in chronic spontaneous urticaria
.
Allergy
.
2021
;
76
(
10
):
2965
81
.
14.
Curto-Barredo
L
,
Archilla
LR
,
Vives
GR
,
Pujol
RM
,
Gimenez-Arnau
AM
.
Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment
.
Acta Derm Venereol
.
2018
;
98
(
7
):
641
7
.
15.
Maurer
M
,
Metz
M
,
Bindslev-Jensen
C
,
Bousquet
J
,
Canonica
GW
,
Church
MK
, et al
.
Definition, aims, and implementation of GA(2) LEN urticaria centers of reference and excellence
.
Allergy
.
2016
;
71
(
8
):
1210
8
.
16.
Weller
K
,
Groffik
A
,
Church
MK
,
Hawro
T
,
Krause
K
,
Metz
M
, et al
.
Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control
.
J Allergy Clin Immunol
.
2014
;
133
(
5
):
1365
72
. 1372.e1-6.
17.
Kocaturk
E
,
Kiziltac
U
,
Can
P
,
Oztas Kara
R
,
Erdem
T
,
Kiziltac
K
, et al
.
Validation of the Turkish version of the Urticaria Control Test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria
.
World Allergy Organ J
.
2019
;
12
(
1
):
100009
.
18.
Maurer
M
,
Weller
K
,
Bindslev-Jensen
C
,
Gimenez-Arnau
A
,
Bousquet
PJ
,
Bousquet
J
, et al
.
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report
.
Allergy
.
2011
;
66
(
3
):
317
30
.
19.
Pereira
ARF
,
Motta
AA
,
Kalil
J
,
Agondi
RC
.
Chronic inducible urticaria: confirmation through challenge tests and response to treatment
.
Einstein
.
2020
;
18
:
eAO5175
.
20.
Ayse Ornek
S
,
Orcen
C
,
Church
MK
,
Kocaturk
E
.
An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria
.
Int Immunopharmacol
.
2022
;
112
:
109198
.
21.
Conlon
NP
,
Edgar
JD
.
Adherence to best practice guidelines in chronic spontaneous urticaria (CSU) improves patient outcome
.
Eur J Dermatol
.
2014
;
24
(
3
):
385
6
.
22.
Mellerowicz
E
,
Weller
K
,
Zuberbier
T
,
Maurer
M
,
Altrichter
S
.
Real-life treatment of patients with cholinergic urticaria in German-speaking countries
.
J Dtsch Dermatol Ges
.
2019
;
17
(
11
):
1141
7
.
23.
Zuberbier
T
,
Munzberger
C
,
Haustein
U
,
Trippas
E
,
Burtin
B
,
Mariz
SD
, et al
.
Double-blind crossover study of high-dose cetirizine in cholinergic urticaria
.
Dermatology
.
1996
;
193
(
4
):
324
7
.
24.
Kocaturk
E
,
Can
PK
,
Akbas
PE
,
Copur
M
,
Degirmentepe
EN
,
Kiziltac
K
, et al
.
Management of chronic inducible urticaria according to the guidelines: a prospective controlled study
.
J Dermatol Sci
.
2017
;
87
(
1
):
60
9
.
25.
Ghazanfar
MN
,
Sand
C
,
Thomsen
SF
.
Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients
.
Br J Dermatol
.
2016
;
175
(
2
):
404
6
.
26.
Exposito-Serrano
V
,
Curto-Barredo
L
,
Aguilera Peiro
P
,
Gomez Armayones
S
,
Serra-Baldrich
E
,
Spertino
J
, et al
.
Omalizumab for the treatment of chronic inducible urticaria in 80 patients
.
Br J Dermatol
.
2021
;
184
(
1
):
167
8
.
27.
Chen
Y
,
Yu
M
,
Huang
X
,
Tu
P
,
Shi
P
,
Maurer
M
, et al
.
Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
.
World Allergy Organ J
.
2021
;
14
(
1
):
100501
.
28.
Maurer
M
,
Schutz
A
,
Weller
K
,
Schoepke
N
,
Peveling-Oberhag
A
,
Staubach
P
, et al
.
Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial
.
J Allergy Clin Immunol
.
2017
;
140
(
3
):
870
3.e5
.
29.
Metz
M
,
Ohanyan
T
,
Church
MK
,
Maurer
M
.
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis
.
J Dermatol Sci
.
2014
;
73
(
1
):
57
62
.
30.
Metz
M
,
Schutz
A
,
Weller
K
,
Gorczyza
M
,
Zimmer
S
,
Staubach
P
, et al
.
Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial
.
J Allergy Clin Immunol
.
2017
;
140
(
3
):
864
7.e5
.
31.
Sussman
G
,
Hebert
J
,
Barron
C
,
Bian
J
,
Caron-Guay
RM
,
Laflamme
S
, et al
.
Real-life experiences with omalizumab for the treatment of chronic urticaria
.
Ann Allergy Asthma Immunol
.
2014
;
112
(
2
):
170
4
.
32.
Brodska
P
,
Schmid-Grendelmeier
P
.
Treatment of severe cold contact urticaria with omalizumab: case reports
.
Case Rep Dermatol
.
2012
;
4
(
3
):
275
80
.
33.
Gastaminza
G
,
Azofra
J
,
Nunez-Cordoba
JM
,
Baeza
ML
,
Echechipia
S
,
Gaig
P
, et al
.
Efficacy and safety of omalizumab (xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial
.
J Allergy Clin Immunol Pract
.
2019
;
7
(
5
):
1599
609.e1
.
34.
Metz
M
,
Ohanyan
T
,
Church
MK
,
Maurer
M
.
Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria
.
JAMA Dermatol
.
2014
;
150
(
3
):
288
90
.
35.
Can
PK
,
Etikan
P
,
Kiziltac
U
,
Kiziltac
K
,
Singer
R
,
Kocaturk
E
.
Fric test revisited: a suggestion for a new scoring system and its correlation with urticaria control test and dermatology life quality index
.
Int Arch Allergy Immunol
.
2019
;
178
(
1
):
76
82
.
36.
Kolkhir
P
,
Gimenez-Arnau
AM
,
Kulthanan
K
,
Peter
J
,
Metz
M
,
Maurer
M
.
Urticaria
.
Nat Rev Dis Primers
.
2022
;
8
(
1
):
61
.
37.
Terhorst-Molawi
D
,
Hawro
T
,
Grekowitz
E
,
Kiefer
L
,
Merchant
K
,
Alvarado
D
, et al
.
Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria
.
Allergy
.
2023
;
78
(
5
):
1269
79
.
You do not currently have access to this content.